Zogenix — Investor Presentation (September 2016)
21 slides from Zogenix's investor presentation, Sep 27, 2016
Slide 1: Company Presentation September 2016
Exhibit 99.1 NASDAQ: ZGNX Company Presentation S e p t e m b e r 2 0 1 6
Slide 2: Forward Looking Statements
Forward “will,” statements of exclusivity marketed the conduct federal, rights described Zogenix care development, for “potential” for state its undertakes Looking RELDAY; drug intreatment regarding: clinical and the and products. potential company’s local testing, Statement and trials, no Zogenix o
Slide 3: Late Stage Development Opportunities in CNS Disorders
Products forSYNDROME) (DRAVET the TreatmentPhase of CENTRAL 3 Ready Phase NERVOUS 3 Initiated SYSTEM January (CNS) 2016Disorders 3 Late Stage Development Opportunities ONCE-MONTHLY ZX008 (low-dose fenfluramine) EPILEPSY SCHIZOPHRENIA
Slide 4: ZX008 Opportunity in Dravet Syndrome
ZX008 and E.U.Dravet Asia-Pacific Syndrome Partnering ZX008 Opportunity Global Ownership 4 Orphan Drug Designation in U.S. and E.U. IND Approved Dec. 2015; Phase 3 Initiation Jan. 2016 Fast Track Designation Intend to Commercialize Directly in U.S.
Slide 5: History of Fenfluramine in Epilepsy
History Dev. syncopes (Belgium) frequency; adjunctive Autism Epilepsia ofand 2016 Fenfluramine 5treatment 7Add seizure Disorders self-induced (doi: on therapy free, 10.1111/epi.13407) with 1987; in4low photosensitive Refractory seizure of17: dose fenfluramine 391-406 frequency fenfluramine Epilepsy
Slide 6: Dravet Syndrome
Dravet Syndrome comorbidities epilepsies blockers (e.g., Polypharmacy ?carbamazepine, ADHD, Intractable, behavior, is standard Severe oxcarbazepine, crouch of Epilepsy care gaitbut Recent lamotrigine) Which no effective, incidence Begins make long-term in study Infancy seizures 1/15,700 treatment Ge
Slide 7: Low Dose Fenfluramine: Long Term Efficacy and Safety
Low 12 Epilepsia for Dravet entire Dose5(2016) syndrome Fenfluramine: years;10 4/10 patients patients, patients Long from age Term seizure 92012 months Efficacy free publication for to and 13 at years least Safety still2(11 on years infenfluramine with Treating Overall confirmatory Dravet Safety the
Slide 8: Evidence of Fenfluramine Effect in Zebrafish Model
Evidence convulsive tance (Control) 8000of -/-seizure-like diFenfluramine (FA) s +/+Sourbron, (Con) behavior, ve Activity Schneider ents loss 6000 in Zebrafish ofet +/+ posture, al.(FA) Serotonergic Mutant m repetitive lati move Model Modulation jerking 4000 of Dravet cumu andasa myoclonic Effective
Slide 9: Prospective Observational Study
Prospective common Study the seizures hypertension 3-month Visits over AED?s Study Full baseline Schoonjans the at clinical entire of baseline: aperiod New study examination, et al Cohort Results valproate period, International of Rapid which Patients (100%), adverse and Child ranged effects, Confir
Slide 10: ZX008 Clinical Program in Dravet Syndrome
ZX0081502, 1501, therapy poor-responders Clinical to stiripentol 1503) Program designed PKregimen studies intoDravet maintain in ? Healthy children Syndrome EUadult 2-18 orphan volunteer, Safety years exclusivity (Study andand Efficacy 1504) pediatric and support Meets ? TwoDravet anticipated double
Slide 11: Design of Phase 3 Safety and Efficacy Studies
Design of Phase1:1:1 Randomization 11 3 Safety Titration and Efficacy 0.2 mg/kg/d Studies Placebo 6 WEEKS Two Identical 12 WEEKS Placebo BASELINE Controlled TREATMENT Maximum Long OBSERVATION Term StudiesZX008 Daily Dose 0.8 mg/kg/d of Open2 Label N = 105 US/Canada: week ZX008 ZX008-1501 Open Label
Slide 12: Key Assessments
Key Assessments convulsive mg/kg/day Doppler echocardiograms vs. seizure Placebo EFFICACY frequency is the ? 12-lead primary Longest Analyses electrocardiogram outcome convulsive for ZX008 measure seizure-free 0.8 12 mg/kg/day SAFETYinterval Adverse vs. Placebo, Clinical events global andLaboratory
Slide 13: ZX008 Phase 3 Status
ZX0083Phase University Phase Results sites 3 Status slower Now Anticipated Study than planned 1501inStudy Q2 ? Activation ?17 1502 Regulatory Initiated of newin Submissions sites January will bolster 2016 on 56% Track enrollment offor study H2 Initiated ?17 sites13 currently in Juneopen 2016with 47%
Slide 14: ZX008 Market Research: Physician Perspectives
ZX008 clinical mechanism grail Recommend game Market performance changer ofRecommend action Research: for is compared this demonstrated Physician 10 syndrome? Suggest to other Perspectives in 1?Not AEDs aAlarger USSuggest Awareness Neurologist patient Majority 0 0sample 2 of 4of ZX008: 6the physicia
Slide 15: Establishing Patient Registry and Cardiac Monitoring
Establishing Use Patient (14/447,369) of Fenfluramine Registry Product 15 and Cardiac in Protection Dravet Monitoring Syndrome ORPHAN Difficult and DRUGElements to STATUS Circumvent of a Provides Future andREMS Expensive 10 Years Program oftoMarket Replicate Ongoing Exclusivity (1) Preclinical Metho
Slide 16: Exploring Use in Other Refractory Pediatric Epilepsy Conditions
Exploring Plan to Evaluate The Usein 2H of ZX008 2016 Started In Other March Refractory 2016 (Phase Orphan2 Pediatric IIS) 16 Epilepsy Conditions Other Refractory Orphan Lennox Gastaut Pediatric Syndrome Epilepsy Conditions Investigator Initiated Study (Phase 2 IIS)
Slide 17: ZX008 Milestones
ZX008 Milestones Initiated ScientificStudy Exhibit (IIS) Room 2016 for Lennox-Gastaut ?Milestones DecemberCompleted ?16syndrome Phase to 3 Dravet Date Expected Initiated syndrome Upcoming U.S. data Phase Milestones ? Q23 ?17 trialZX008 (Study Interim Dravet 1501) results for syndrome from Dravet on-
Slide 18: RELDAY: Once-Monthly Antipsychotic for Schizophrenia
PHASE 3 READY Schizophrenia Proprietary Subcutaneous Once-Monthly Antipsychotic Highly Differentiated Profile Worldwide Rights Search Ongoing for Development and Commercialization Partner 18
Slide 19: RELDAY Differentiated Profile
RELDAY complicated need for reconstitution Has loading a Differentiated dose prior regimens to LAI use Intellectual Initiation Profile A Proven, dose Property identical Effective issued to maintenance and and pending Safe Molecule dose patents Once-monthly for through the Treatment at least dosing 2
Slide 20: Financial Highlights
Financial capital respectively advance Highlights 20 from Cash Endo(as International of 6-30-16)(2) $128M Fully Debt diluted (1)shares $20Minclude (as of 6-30-16) options toCommon purchaseShares 3.3 million Outstanding shares and (as of warrants 6-30-16) to 24.8 purchase M Fully 2.0 million Diluteds
Slide 21: Promising Pipeline
NASDAQ: PROMISING PIPELINE PHASE 3 PROGRAM INITIATED FOR ZX008 FULLY FUNDED CLINICAL PROGRAMS SIGNIFICANT NEAR-TERM MILESTONES EXPERIENCED TEAM IN PLACE